WCA
MREO

Windsor Creek Advisors’s Mereo BioPharma MREO Stock Holding History

Windsor Creek Advisors’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,000
Closed -$48K – 159
2021
Q2 		$48K Buy
+15,000
New +$50.3K 0.01% 168

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Windsor Creek Advisors's MREO Position: Q3 2021 in Review

Windsor Creek Advisors sold out of Mereo BioPharma (MREO) in Q3 2021, closing a stake of 15,000 shares — an estimated $48K sold.

Windsor Creek Advisors first reported a position in MREO in Q2 2021 and held it in 1 quarter. The position peaked at $48K in Q2 2021. 63 funds tracked by Wall St. Rank hold MREO as of Q3 2021.

  • Windsor Creek Advisors reported no remaining Mereo BioPharma position as of Q3 2021 after selling out during the quarter.
  • Windsor Creek Advisors sold 15,000 Mereo BioPharma shares in Q3 2021, an estimated $48K.
  • Windsor Creek Advisors first reported a position in Mereo BioPharma in Q2 2021 and held it in 1 quarter.
  • Windsor Creek Advisors's Mereo BioPharma position peaked at $48K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2021.

Based on Windsor Creek Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.